🇧🇷·19h agoRegulatory
Interfarma na Imprensa: Interfarma ressalta importância de previsibilidade regulatória após adiamento da Resolução CMED nº 3/2025
Publisher
I
Interfarma Brazil
Brazil
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on interfarma.org.br
Leave the platform to read the original full article on the publisher site.
Source: Interfarma Brazil
Scope: Regulatory
Related coverage
More related coverage
MHRA UK·4h ago
Guidance: The Innovative Devices Access Pathway (IDAP)
IFPMA Global·7h ago
Sixth resumed meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement: PABS instrument
NAFDAC Nigeria·18h ago
Note to Industry on Requirement for Bioequivalence Study
Interfarma Brazil·21h ago